Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Authors :: Cicardi, M.
Banerji, A.
Bracho, F.
Malbran, A.
Rosenkranz, B.
Riedi, M.
Bork, K.
Lumry, W.
Aberer, W.
Bier, H.
Bas, M.
Greve, J.
Hoffmann, T.K.
Farkas, H.
Reshef, A.
Ritchie, B.
Yang, W.
Grabbe, J.
Kivity, S.
Kreuz, W.
Levy, R.J.
Luger, T.
Obtulowicz, K.
Schmid-Grendelmeier, P.
Bull, C.
Sitkauskiene, B.
Smith, W.B.
Toubi, E.
Werner, S.
Anne, S.
Bjorkander, J.
Bouillet, L.
Cillari, E.
Hurewitz, D.
Jacobson, K.W.
Katelaris. C.H.
Maurer, M.
Merk, H.
Bernstein, J.A.
Feighery, C.
Floccard, B.
Gleich, G.
Hebert, J.
Kaatz, M.Keith, P.
Kirkpatrick, C.H.
Langton, D.
Martin, L.
Pichler, C.
Resnick, D.
Wombolt, D.
Romero, D.S. Fernandez
Zanichelli, A.Arcoleo, F.
Knolle, J.
Kravec, I.
Dong, L.
Zimmermann, J.
Rosen. K.
Fan, W.-T
Source :: The New England Journal of Medicine. August 5, 2010, Vol. 363 Issue 6, p535, 10 p.
Publication Year :: 2010
Abstract: A study was conducted to evaluate the efficacy and safety of icatibant, a new bradykinin-receptor antagonist in the treatment of hereditary angioedema. Results indicated that in the case of such patients, icatibant was found to be quite effective and having positive outcomes as compared to placebo or tranexamic acid.

Subjects :: Tranexamic acid -- Health aspects
Tranexamic acid -- Comparative analysis
Angioneurotic edema -- Genetic aspects
Angioneurotic edema -- Drug therapy
Bradykinin -- Health aspects
Bradykinin -- Comparative analysis

Tools